The Medicare CBD program comes with a lot of acronyms and technical terms. Here's every one of them explained in plain language so you can have an informed conversation with your doctor.
Related: Complete Guide | Full FAQ | How It Works
ACO, Accountable Care Organization
A network of doctors, hospitals, and other healthcare providers who work together to coordinate care for a defined group of Medicare patients. ACOs are accountable for the total cost and quality of care for their patient population. Being in an ACO is the first step toward accessing the Medicare CBD benefit, but not all ACOs participate in the specific program types that offer the benefit.
ACO REACH, Accountable Care Organization Realizing Equity, Access, and Community Health
A specific CMS Innovation Center model, one of the three program types that can offer the Medicare CBD benefit. ACO REACH organizations serve general Medicare patients with chronic conditions. This is the broadest pathway to the CBD benefit. If your primary care doctor is in a large medical group or health system, there's a reasonable chance they're in an ACO REACH organization.
BEI, Beneficiary Engagement Incentive
The specific benefit type within the CMS Innovation Center models that allows CBD products to be provided to patients. The full name is Substance Access BEI. When a participating organization "elects the BEI," it means they've specifically chosen to offer this particular benefit alongside their regular program participation.
CMS, Centers for Medicare and Medicaid Services
The federal agency that runs Medicare and Medicaid. CMS created and oversees the Innovation Center models that provide the CBD benefit. When program guidelines reference "CMS requirements," they mean requirements set by this agency. Their Innovation Center website is at innovation.cms.gov.
COA, Certificate of Analysis
The lab report issued by an independent laboratory for a specific batch of CBD product. A COA covers: the cannabinoid panel (how much CBD, THC, and other cannabinoids are present), heavy metals panel, pesticide panel, microbial panel, and residual solvents panel. CMS requires third-party COAs for all products used in the program. View ours at /pages/hemp-lab-results-coa.
Delta-9 THC
The primary psychoactive compound in cannabis. The Farm Bill defines hemp as cannabis containing no more than 0.3% delta-9 THC by dry weight. This is the key number that distinguishes legal hemp from marijuana under federal law. All products in the Medicare CBD program must meet this limit.
Enhancing Oncology Model (EOM)
One of the three CMS Innovation Center program types that can offer the Medicare CBD benefit. The EOM specifically serves cancer patients. Oncology practices enrolled in this model can provide CBD to eligible cancer patients for pain, chemotherapy side effects, and related symptoms. If your doctor is an oncologist, this is the relevant program type to ask about.
Farm Bill Compliant
Means the hemp was grown and processed in compliance with the 2018 Agriculture Improvement Act (Farm Bill), which legalized hemp at the federal level. Farm Bill compliant hemp contains less than 0.3% delta-9 THC and was grown under a state or federal hemp program authorized by the USDA. All products in the Medicare CBD program must be Farm Bill compliant.
Implementation Plan
The document a participating organization submits to CMS before they can begin distributing CBD to patients. The plan describes which products they'll use, dosing protocols, patient eligibility criteria, distribution process, and safeguards. CMS must approve the plan before any products can be provided. This is a required organizational step, not a patient-level requirement.
LEAD Model, Longitudinal Enhanced Advanced Dementia Model
The third CMS Innovation Center program type that can offer the Medicare CBD benefit, starting January 1, 2027. The LEAD Model serves patients in long-term enhanced care arrangements. If you're in long-term care or anticipate transitioning to it, this program type becomes relevant in 2027.
Oral Solution
A liquid CBD product taken orally by swallowing, distinct from a tincture taken sublingually. Oral solutions are sometimes used in clinical settings. Like tinctures and gummies, they count as oral products and qualify under the Medicare CBD program.
Qualifying Physician
A physician whose organization participates in one of the three qualifying CMS Innovation Center model types (ACO REACH, Enhancing Oncology Model, or LEAD Model) and whose organization has elected the Substance Access BEI benefit. Not every Medicare physician is a qualifying physician for this program.
Substance Access BEI
The official full name of the Medicare CBD benefit. BEI stands for Beneficiary Engagement Incentive. The Substance Access BEI allows participating CMS Innovation Center organizations to provide qualifying oral CBD products to eligible Medicare patients at no charge, up to $500 per year.
Total THC
The combined amount of all THC forms in a product, delta-9 THC, delta-8 THC, delta-10 THC, THC-A, and other variants. The Medicare CBD program requires less than 3mg total THC per serving. This is distinct from just delta-9 THC. Always check the COA for total THC, not just delta-9, when evaluating product compliance.
USDA Organic
A federal certification from the USDA National Organic Program confirming that a farm operates without synthetic pesticides, synthetic fertilizers, or GMOs, undergoes annual inspections, and maintains detailed compliance records. Not required for the Medicare CBD program but a strong quality and safety marker. Our hemp farm in Wilmore, Kentucky is USDA Organic certified.
